Previous 10 | Next 10 |
home / stock / pcsa / pcsa articles
Processa Pharmaceuticals Inc (NASDAQ: PCSA) shares are trading lower by 21.7% to $0.64 Wednesday morning after the company said it recently ha...
U.S. stocks traded mixed this morning, following the release of PPI data on Wednesday. Following the market opening Wednesday, the Dow traded down ...
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dippe...
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday. Lipella Pharmaceuticals Inc. (NASDA...
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares surged 95.5% to $0.6226 in pre-market trading after jumping 34% on Thursday. Urgent.ly Inc....
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently rega...
Gainers LQR House Inc. (NASDAQ: LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, se...
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indic...
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreeme...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...